A ATARA BIOTHERAPEUTICS INC
| Market Cap | $48.01M |
| P/E Ratio | 2.33 |
| Forward P/E | -25.61 |
| Dividend Yield | — |
| Beta | -0.40 |
| 52W Range | $3.92 - $19.15 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 19 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Grant-Huerta YaninaChief Accounting Officer | Sale | 377 | $5.08 | $1.92K | 02 Mar 2026 | 04 Mar 2026 |
| Grant-Huerta YaninaChief Accounting Officer | Sale | 24 | $5.08 | $121.85 | 02 Mar 2026 | 04 Mar 2026 |
| Nguyen AnhCoPresident and CEO | Sale | 1,442 | $5.09 | $7.34K | 02 Mar 2026 | 04 Mar 2026 |
| Grant-Huerta YaninaChief Accounting Officer | Sale | 100 | $5.08 | $508.3 | 02 Mar 2026 | 04 Mar 2026 |
| Grant-Huerta YaninaChief Accounting Officer | Sale | 1,603 | $5.08 | $8.14K | 02 Mar 2026 | 04 Mar 2026 |
| Nguyen AnhCoPresident and CEO | Sale | 1,298 | $5.09 | $6.60K | 02 Mar 2026 | 04 Mar 2026 |
| Nguyen AnhCoPresident and CEO | Sale | 58 | $5.08 | $294.64 | 02 Mar 2026 | 04 Mar 2026 |
| Nguyen AnhCoPresident and CEO | Sale | 198 | $5.08 | $1.01K | 02 Mar 2026 | 04 Mar 2026 |
| Panacea Innovation Ltd | Sale | 80,554 | $6.07 | $489.02K | 12 Jan 2026 | 14 Jan 2026 |
| Nguyen AnhCoPresident and CEO | Sale | 56 | $13.19 | $738.53 | 17 Nov 2025 | 19 Nov 2025 |
| Grant-Huerta YaninaChief Accounting Officer | Sale | 1,645 | $13.19 | $21.69K | 17 Nov 2025 | 19 Nov 2025 |
| Nguyen AnhCoPresident and CEO | Sale | 2,859 | $13.19 | $37.70K | 17 Nov 2025 | 19 Nov 2025 |
| Grant-Huerta YaninaChief Accounting Officer | Sale | 74 | $13.19 | $976.13 | 17 Nov 2025 | 19 Nov 2025 |
| Grant-Huerta YaninaChief Accounting Officer | Sale | 85 | $13.19 | $1.12K | 17 Nov 2025 | 19 Nov 2025 |
| Anhco NguyenPresident and CEO | Sale | 56 | $13.19 | $738.53 | 17 Nov 2025 | 19 Nov 2025 |
| Anhco NguyenPresident and CEO | Sale | 2,859 | $13.19 | $37.70K | 17 Nov 2025 | 19 Nov 2025 |
| Yanina Grant-HuertaChief Accounting Officer | Sale | 74 | $13.19 | $976.13 | 17 Nov 2025 | 19 Nov 2025 |
| Yanina Grant-HuertaChief Accounting Officer | Sale | 85 | $13.19 | $1.12K | 17 Nov 2025 | 19 Nov 2025 |
| Yanina Grant-HuertaChief Accounting Officer | Sale | 1,645 | $13.19 | $21.69K | 17 Nov 2025 | 19 Nov 2025 |
Frequently Asked Questions
What is ATRA stock price today?
ATARA BIOTHERAPEUTICS INC (ATRA) is currently trading at $6.66. The stock has a 52-week range of $3.92 to $19.15 and a market capitalization of $48.01M.
Is ATRA a good stock to buy in 2026?
ATARA BIOTHERAPEUTICS INC has a P/E ratio of 2.3 (forward P/E: N/A), a dividend yield of none, and 1-year performance of +5.2%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ATRA stock?
There have been 19 insider transactions for ATRA in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ATRA stock performed over the past year?
ATARA BIOTHERAPEUTICS INC (ATRA) has returned +5.2% over the past 12 months. The stock traded between $3.92 and $19.15 during this period, and is currently at $6.66.
Which hedge funds own ATRA (ATARA BIOTHERAPEUTICS INC)?
0 tracked hedge funds currently hold ATRA in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ATRA's market cap and valuation?
ATARA BIOTHERAPEUTICS INC (ATRA) has a market capitalization of $48.01M. The trailing P/E ratio is 2.3 and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is ATRA's revenue and profitability?
ATARA BIOTHERAPEUTICS INC reported revenue of $151.93M with net income of $23.40M and a profit margin of 0.15%. The stock has a beta of N/A.
What sector is ATRA in and who are its biggest institutional holders?
ATARA BIOTHERAPEUTICS INC (ATRA) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.